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Introduction
Primary liver cancer is the eighth most common human tumor world-wide. Hepatocellular carcinoma (HCC), representing the most prevalent histological form, develops in around 90% of cases with a background of chronic active hepatitis and cirrhosis. 1, 2 This in turn has two major implications: an apparently isolated, small tumor nodule is in fact surrounded by a number of liver cell clones which have the potential to evolve into tumor nodules. In addition, due to the underlying chronic liver disease, any treatment should take into consideration the risk of inducing severe liver failure. Small, isolated tumor nodules amenable to surgical resection are only identified in around 10% of all patients evaluated for HCC. [3] [4] [5] Furthermore, recurrence was frequently observed after surgical resection with a mean probability of 5 years averaging 80%. [5] [6] [7] Liver transplantation may be advocated but its efficacy in small tumor management should be balanced with the risk of transplantation itself and the lack of organ donors. [8] [9] [10] In advanced tumors, where surgery is contraindicated, there was no solid evidence for the efficacy of procedures such as percutaneous ethanol injection, transarterial chemoembolization, systemic chemotherapy or hormonotherapy. gene therapy as a future strategy for treating HCC. Indeed, promising results have been obtained from a variety of tumors, and in most cases using in vitro tests. We and others demonstrated that retroviral and adenoviral vectors can infect HCC-derived human cell lines in vitro; in addition, it has been possible specifically to target the expression of a gene inserted into such vectors in hepatoma cells by using regulatory sequences of genes specifically expressed in hepatoma cells, such as ␣-fetoprotein. [14] [15] [16] [17] [18] These in vitro data have been substantiated by the demonstration of an efficient gene transfer in vivo in tumors induced in nude mice upon injection of HCC cell lines. 15 It is however important to emphasize that these approaches still only partially reflect the in vivo situation. In particular, tumors induced in nude mice may markedly differ from human HCC. This concern could explain the results of recent investigations, in our group and from another study, in HCCs induced by chemical carcinogens or developed in transgenic mice reporting a low transduction efficacy of tumorous cells in vivo. 15, 19 These experiments, however, did not take into account the specific aspects of HCC vascularization and in most cases, the viral vectors were administered by portal injection. It is well known that, in humans, HCCs have predominantly an arterial blood supply. 20 Thus, a comprehensive characterization of the animal models, taking into account the tumor vascularization, as well as a detailed analysis of the efficiency of the different routes of administration, are mandatory to develop such approaches further.
In this study, we investigated the tumor vascularization of DEN-induced HCCs in the rat using a computerized tomography (CT) scanner and a bolus intravenous injection of an iodinated contrast material. Then, we compared the transduction efficiency of the tumorous cells using a recombinant adenoviral vector, AdCMVlacZ, via various routes of administration (intraportal injection, selective injection through the hepatic artery and direct injection into the tumor). Our results showed an enhanced efficiency of gene transfer via intra-arterial administration, increasing gene expression in tumorous cells and dysplastic nodules. This suggests that arterial infusion, targeting dysplastic nodules, might be a feasible approach for gene therapy of HCCs.
Results
Vascular blood supply of hepatocarcinomas in DENtreated rats Six rats with liver tumors larger than 8 mm diameter were studied and compared with five normal rats. CT scans of the DEN-induced tumors were monitored after injection of a contrast medium into the tail vein. 21 The scanning images showed a successive opacification of the vena cava, the aorta, the tumorous area and finally, the portal vein ( Figure 1, upper panel) . This was demonstrated by the enhancement curves displayed in the lower panel ( Figure 1 ). The arterial and portal blood supplies of the nontumorous and tumorous areas were also studied. In each rat, each selected slice included tumorous and nontumorous areas. In Table 1 , the arterial blood flow in the tumors (3.8 ± 2.9 ml/min/g) was significantly higher than that in the nontumorous parenchyma (0.5 ± 0.5 ml/min/g), and in the normal liver parenchyma (0.6 ± 0.6 ml/min/g) (P Ͻ 0.05), resulting in a high tumour perfusion index (TPI) of 67%. By contrast, in the nontumorous liver parenchyma of HCC-bearing rats, the arterial blood supply (0.5 ± 0.5 ml/min/g) was lower than the portal blood supply (3.2 ± 3.2 ml/min/g), leading to a low perfusion index (LPI) of 13%. This latter value was comparable with the LPI of normal rats (12%). Thus, the predominance of the arterial vascularization of DEN-induced rat HCCs suggests that gene transfer via selective administration through the hepatic artery could provide a strategy to target the tumor nodules.
Improvement of in vivo gene transfer into tumorous cells by selective hepatic intra-arterial administration of AdCMVlacZ Previous studies showed a low ratio of transduced tumorous to nontumorous cells via either intraportal, nonselective intra-arterial, or intratumoral injection of recombinant adenovirus. 15 To improve the efficiency of in vivo gene transfer into tumorous cells, we raised the question whether selective administration of recombinant adenovirus through the hepatic artery could increase the ratio of transduced tumorous to nontumorous cells. In the present study, we examined the adenovirus-mediated gene transfer and expression of lacZ in tumorous cells of DEN-induced rat HCCs by selective injection of AdCMVlacZ via the hepatic artery. These results were compared with the results obtained from rats injected with adenoviruses by intraportal or intratumoral routes. Figure 2 (a-f) depicts various X-gal-stained liver specimens obtained from rats injected with adenoviruses by the three respective routes of administration: hepatic artery, portal and direct injection. As observed in Figure 2 (a and b), gene transfer into tumors was significantly increased and that of the nontumorous liver decreased after injection by intra-arterial route, in comparison to low cell transduction into tumors and high cell transduction in nontumorous and peritumorous areas after intraportal injection (Figure 2c and d) . In addition, as shown in Figure 2a , the transduction of dysplastic nodules could be differentiated after intra-arterial administration of AdCMVlacZ, as well as the transduction of tumorous cells of the large tumors, particularly in the central core. Such a labelling visualization of the dysplastic nodules and large tumors was absent when using intraportal injection of recombinant adenovirus. It is conceivable that administration of AdCMVlacZ by the intraportal route would also transduce the dysplastic nodules in the nontumorous areas. However, such nodules are probably hidden due to the strong background of nontumorous cells (Figure 2c ). The staining of tumorous cells limited to the sites of injection after intratumoral administration of AdCMVlacZ is shown in Figure 2 Figure 3a showed an increased labeling intensity of tumorous cells after hepatic arterial administration of AdCMVlacZ, compared with the weak tumorous cell labeling after portal administration of the same recombinant adenovirus ( Figure 3c ). As observed by gross microscopy, Figure 3b showed an intense cell labelling in a dysplastic nodule after arterial injection. These results demonstrate that arterial injection of AdCMVlacZ allowed a far more efficient transduction of tumor cells and dysplastic nodules (Figure 3a and b) than portal injection of AdCMVlacZ. The latter route yielded rather efficiently transduced non tumorous and peritumorous cells (Figure 3c and d) .
Finally, we performed a comparative study of ␤-galexpressing cells in tumors of both sizes (Ͻ and Ͼ8 mm) after either intra-arterial or intraportal injection of AdCMVlacZ (P Ͻ 0.05) (Figure 4a and b). The comparative study allowed us to score and classify the percentage of efficiently transduced tumors according to the level of positively transduced cells. It clearly showed that the intra-arterial route of administration of recombinant adenovirus improved the efficacy of gene transfer and expression of ␤-gal in tumors of both sizes, yielding particularly 35 to 60% of transduced tumors. Remarkably, 15 to 25% of tumorous cells in tumors Ͻ8 mm were transduced. This suggests the possibility for early treatment of HCCs using this method.
Quantitative evaluation of gene transfer
To provide a quantitative evaluation of gene transfer after intraportal, intra-arterial or intratumoral administration of AdCMVlacZ, the images from 10-m cryosections of the relevant tumor, stained with X-gal and counterstained with eosin, were digitalized and analyzed as indicated in Materials and methods. 
Figure 1 Liver CT scan study of a DEN-treated tumorous rat after contrast medium injection into the tail vein. Upper panel, The contrast agent was injected at t = 2 s. Successive opacification of (a) inferior vena cava (immediate), (b) aorta (6 s), (c) tumorous area (8 s) and (d) portal vein (12 s). Lower panel, enhancement curves of the aorta, the tumor, the nontumorous liver and the portal vein. Time is expressed in s.
depicts the digitalized image from a nontumoral area after portal injection of AdCMVlacZ, and the corresponding image showing a positively labelled area expressing ␤-gal after thresholding. Two animals, representative of each group, were studied as reported in Materials and methods. Table 2 reports the percentage of cells efficiently transduced in various areas: nontumorous, peritumorous and tumors of both sizes Ͻ and Ͼ8 mm.
In agreement with the gross microscopy examination, expression of ␤-gal in small tumors (Ͻ8 mm) was improved when AdCMVlacZ was injected via the intraarterial route as compared with the injection of the same Table 1 CT scan study of DEN-treated rat liver vascularization
Liver normal rats Liver HCC-bearing rats Tumor HCC-bearing rats
Arterial blood supply 0.6 ± 0.6 0.5 ± 0.5 3.8 ± 2.9 (ml/min/g) Portal blood supply 4.2 ± 1.1 3.2 ± 3.2 1.9 ± 1.9 (ml/min/g) Arterial perfusion index LPI = 12 LPI = 13 TPI = 67 (%)
The arterial blood supply of nontumorous (LPI) and tumorous (TPI) areas of DEN-treated rats is expressed as a percentage of the total perfusion, which includes the arterial and portal blood supplies. The results of the arterial and portal blood supplies are expressed as mean values ± s.d. (P Ͻ 0.05).
recombinant adenovirus via an intraportal route. The same observation was made in tumors of size Ͼ8 mm. In addition, the level of positively stained cells was comparable to that observed after intratumoral injection of recombinant adenovirus into tumors of the same size. No difference was seen in the peritumorous areas of each respective sample derived from liver specimens obtained after either arterial, or portal, or direct injection of AdCMVlacZ.
Discussion
This study provides information which may be useful for designing gene therapy protocols to treat HCCs. First, we showed that the global efficacy of tumor cell transduction in vivo by adenoviral vectors was clearly dependent on the stage of tumor growth, being very low in large tumors, but significantly increased in early small tumor nodules. We also provided detailed analysis of the vascularization of HCCs induced in rats by DEN and showed that, as for human tumors, the predominant vascularization of these tumors is arterial. Given this observation, we have established that it was possible to increase the ratio of tumorous to nontumorous cell transduction significantly by selectively injecting the viral preparation into the hepatic artery. This result points to the possibility of decreasing the potential toxic effects induced by some 'therapeutic' genes inserted in these vectors on nontumorous cells.
In the first part of our work, we studied the vascularization of DEN-induced HCCs in the rat using a dynamic CT scan approach. Several methods have been developed in order to determine the arterial/portal ratio in liver vascularization, using radionuclide imaging. 22 Recently, some studies pointed out the importance of dynamic CT scan approaches, especially using Ultrafast CT for the evaluation of hepatic perfusion changes in patients with liver diseases. 23, 24 The use of a dynamic CT scan indeed allowed us to calculate the respective contribution of arterial and portal blood flow in delimited areas of the rat liver. In our experimental model of DEN-induced HCCs, we showed that, as reported for human HCCs, 20, 25 the tumor vascularization was mostly dependent on the hepatic artery (Table 2) . Therefore, although technically difficult in a rat model, injecting viral or nonviral vectors selectively via the intrahepatic artery instead of intraportal injection is mandatory to provide data relevant for human tumors (our present results and Bookstein et al 26 ). Given these observations, we precisely analyzed the relative efficacy of adenoviral vector delivery to DENinduced rat HCCs when using three different routes of administration: intraportal, intra-arterial and intratumoral. Our data demonstrate that, when compared with intraportal injection, selective administration of the viral preparation in the hepatic artery is of interest for at least three reasons. First, selective arterial injection allowed an overall improvement in the efficiency of gene transfer into tumors. Second, selective arterial administration allowed a selective and efficient targeting of some dysplastic nodules; in fact, under these conditions, we were able to show a marked increase in the number of the transduced dysplastic cells, compared with nontumorous cells. In DEN-treated rat liver, all dysplastic nodules will not evolve to HCC. 27 That only a fraction of these dysplastic nodules would be arterialized might account for such a different evolution, since modifications in the vascularization of liver dysplastic areas are probably a critical step in carcinogenesis, allowing progression from a dysplastic nodule to cancer. 28 Thus, a dysplastic nodule 'selected' by the arterial injection would be at high risk of evolving to HCC. In this view, arterialized preneoplastic nodules could be accessible to gene therapy, allowing a 
u. per animal) through the hepatic artery (a, b) or the portal vein (c, d), or directly into the tumor (e, f). (a, b) Macroscopic appearance after arterial injection. (a) ␤-gal expression into the centre of a 1-cm tumor; (b) dysplastic nodule very efficiently transduced; (c) necrotic area. (c, d) Macroscopic appearance after intraportal injection. (e, f) Macroscopic appearance after direct injection into two tumors showing a high transduction efficiency along the sites of injection.
very early treatment of HCCs. Third, transgene expression in the nontumorous liver appeared to be lower after intra-arterial than after intraportal injection (Figure 3a-d) . This result may corroborate the low arterial blood supply in nontumorous areas, as compared with that observed in tumors (Table 1) . Thus, the arterial administration would mostly target a direct expression of the transgene into the tumors. This point is of major interest in light of the high toxicity of some therapeutic approaches such as those based on the transfer of the herpes simplex thymidine kinase (tk) gene. In this protocol the tk gene converts ganciclovir to its active metabolite and thus kills both proliferating infected cells and adjacent nontransduced cells ('bystander' effect). 29 Such 
u. per animal) through the hepatic artery (a, b) or the portal vein (c-e). (a) Nontumorous (NT) and tumorous areas (T) after arterial injection. (b) Dysplastic nodule highly transduced after intra-arterial injection. (c) Nontumorous (NT) and tumorous areas (T) after portal injection. (d) Nontumorous liver transduction after intraportal administration. (e) Digitalized image of nontumorous area as indicated in Materials and methods. (f) The corresponding image showing the same positively labelled area expressing ␤-gal after thresholding. Arrows indicate the periphery of the tumor.
a protocol, although it should kill only dividing cells, may be very toxic for the nontumorous liver in DENtreated rats. 30, 31 We have observed the toxicity of the HSVtk in normal liver when using portal administration of the viral preparation (manuscript submitted). Selective injection into the hepatic artery, by decreasing the adenoviral infection in the nontumorous liver, should decrease the toxicity of this therapeutic approach. Adenovirusmediated gene transfer, by direct injection of the adenoviral preparation into the tumor, is an alternative possi- The number of tumors scored in each group is also indicated.
bility to be considered. Our study indeed showed that its overall efficacy was close to that observed with arterial administration. A major advantage is obviously its simplicity, and therefore one might envisage repeated injections to enhance gene transfer further. On the other hand, we believe that this approach shows important limitations: only tumors of a sufficient size will be treated, and we have shown that the efficacy of gene transfer was generally quite low at this stage; furthermore, it will not be possible to treat the adjacent dysplastic nodules which show both a high malignant potential and a higher rate of adenoviral infection. The mechanisms accounting for an overall low efficacy of gene transfer to HCC tumor cells are not known. They probably involve the so-called capillarization of tumor sinusoids. 32, 33 Modification in the expression of cellular receptors for adenovirus in tumor cells might also be implicated. We also attempted to enhance gene transfer efficacy to the tumor cells by mixing the adenoviral preparation with small amounts of Lipiodol (iodised oil, Guerbet, Aulnay sous bois, France). Uptake of this compound by HCCs has been well demonstrated. However, no increase in tumor cell transduction by either intraarterial or intratumoral administration was observed (unpublished results).
In conclusion, our work shows that arterial infusion of adenoviral preparation greatly improves gene transfer in experimental HCC and premalignant nodules, although many problems obviously remain. Our results emphasize the need for a study of tumor vascularization in the experimental design studies of gene therapy for HCC. Altogether, our investigation further delineated the general outline of gene therapy for HCCs. Whatever the target gene (suicide gene associated with a cytokineencoding gene, or tumor suppresser gene), it is mandatory to consider gene expression targeting to tumor cells using both selective administration into the hepatic artery and regulatory sequences specifically expressed in hepatic tissues. This might allow a compromise between sufficient tumor cell transduction and nontumor cell toxicity.
Materials and methods

Adenoviral vector
The E1-deleted recombinant adenovirus AdCMVLacZ contains the E. coli lacZ gene under the control of the cytomegalovirus (CMV) early major promoter. 17 The recombinant adenovirus was amplified on 293 cells and purified by two ultracentrifugation steps on cesium chloride gradient. Stocks of virus were stored at −80°C until use. The titer of each adenoviral preparation was determined by plaque assay on 293 cells.
Induction of primary liver tumors
Primary liver carcinomas were induced in male Wistar rats weighing 120-150 g by a daily supply of diethylnitrosamine (DEN) in the drinking water over 2 months, as previously described. 15 Several tumors were detected in 90% of the animals within 3 months after beginning the exposure to the carcinogen. All animal experiments were reviewed and approved by institutional committees for animal care and use and for recombinant DNA research (Ministère de l'Agriculture, France).
Imaging study of tumor vascularity
This study was performed on a spiral computerized tomography scanner (CT scan) (Prospeed Advantage; General Electric, Milwaukee, WI, USA). Six rats were anesthetized by intraperitoneal injection of 0.3 ml/kg ketamine. A 25 gauge butterfly was placed into the tail vein. A first CT scan acquisition was performed without contrast medium injection in order to select a tumorous area in the liver. Then, a continuous acquisition was performed on the selected area during the intravenous bolus administration of contrast medium (1 ml/kg Omnipaque 300; Nycomed, Oslo, Norway). The sequence parameters allowed a spatial resolution of 0.3 mm and a temporal resolution of 0.2 s during 30 s (150 images). Image intensities obtained from the nontumorous liver, the tumor area, the portal vein and the aorta, respectively, were determined by image analysis as means of the region of interest (ROI). The liver perfusion index which represents the percentage of the arterial blood flow from the total blood flow for the studied ROI was calculated using a deconvolution analysis. Numerical values obtained from the images were plotted with a home-made software written in IDL (interactive data language) on a Unix workstation. For each animal, two perfusion indexes could be obtained, TPI (tumor perfusion index) and LPI (liver perfusion index). These parameters represent the percentage of arterial input in the organ perfusion, and are calculated as follows:
TPI (%) = tumor arterial perfusion/total tumor perfusion LPI (%) = liver arterial perfusion/total liver perfusion The values were compared with the liver perfusion indexes obtained in five normal rats under the same experimental conditions. The results were compared between the groups of rats using the distribution free Mann and Whitney test. 34 Administration of recombinant adenoviral vector to rats bearing DEN-induced HCCs Three modalities of administration to rats bearing DENinduced HCCs were defined: the intraportal, intratumoral injection and the selective injection via the hepatic artery. For each mode of injection, AdCMVlacZ, diluted in 1 ml phosphate-buffered saline (PBS) before injection, was used at a single dose of 10 10 plaque forming units (p.f.u.) per animal. The number of animals studied by each route of administration is summarized in Table 3 .
(1) Intraportal injection: This study was performed in six rats. The recombinant adenovirus was injected by puncture of the portal vein using a 30 gauge needle, in a volume of 1 ml.
(2) Selective injection via the hepatic artery: Eight rats were studied. After dissection of the hepatic pediculus, the celiac artery was clamped. Then, a 30 gauge needle was introduced into the hepatic artery via the gastroduodenal artery, and 0.5 ml of AdCMVlacZ diluted in PBS was injected. After injection of the adenoviral solution, the gastroduodenal artery was ligated and the blood flow was re-established into the celiac and the hepatic artery. The duration of the arterial blood flow interruption varied between 5 and 15 min. No decease was observed within the 4 days following the experiment.
(3) Intratumoral injection: The recombinant adenovirus diluted in PBS was directly injected into six tumors of four rats, using a 30 gauge needle. The volume comprised between 0.1 and 1 ml.
Histochemical detection of transgene expression
Four days after injection, animals were laparotomized and killed. The livers were washed by portal infusion of PBS and fixed in 4% paraformaldehyde in PBS (w/v). Specimens of various sizes were removed from different regions of the liver including tumorous and nontumorous areas. Each specimen was divided in two parts. One half was incubated for 10 h in X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactosidase) staining solution at 30°C, and the second half snap frozen in liquid nitrogen for cryosection. 10-m Cryosections of the liver pieces were stained with X-gal at 30°C for 5 h and counterstained with eosin and hematoxylin.
Gross examination of each specimen, which included tumorous and nontumorous areas was performed after staining with X-gal. For each piece, staining of nontumorous (NT), peritumorous (PT), dysplastic areas and tumors (T), was recorded. Two groups of tumors according to their diameter (Ͻ or Ͼ8 mm) were analyzed ( Table 3) . We studied 18 tumors from six rats injected with AdCMVlacZ via intraportal route, 32 tumors from eight rats injected with AdCMVlacZ via intra-arterial route, and six tumors injected directly with the recombinant adenovirus. The grading of cell staining intensity was evaluated in 5 noncontiguous fields of each respective area (two in the center and three within the peripheral area), and expressed as follows: Ͻ1%, 1-5%, 5-15% and 15-25% of ␤-galactosidase (␤-gal)-expressing cells. A mean value was calculated for each gradation. The results were compared between the groups of rats using the distribution free Mann and Whitney test. 34 Histochemical quantification of gene transfer efficacy Images from 10-m cryosections stained with X-gal solution and counterstained with eosine were visualized on an Axiophot transmission microscope (Carl Zeiss, Le Pecq, France) using low numeric aperture lenses (10 ×, 0.25 NA), and digitalized in a matrix 768 × 512 pixels using a cooled 3CCD camera module (Lhesa, Paris, France). They were then analyzed under the Matrox Inspector 1.71 software (Matrox Electronic Systems, CA, USA) for Windows 3.1. Briefly, the first step consisted of switching the color image to a binarized image (256 Gy levels). Positive areas were assessed by thresholding. The same thresholding was applied constantly for each sample. Five microscopical fields with a conserved morphology and regenerating the periphery of the tumor and the normal tissue surrounding the lesions were analyzed. In a second step, acellular areas within the microscopic field were subtracted and the results, expressed by labelled surfaces, reflected the percentage of ␤-gal-expressing cells. The digitalized images of the X-gal-stained and eosin-counterstained cryosections were monitored for all 18 animals. All the images were found equivalent with respect to X-gal staining. Accordingly, we selected and studied nontumorous (NT), peripheric tumorous (PT) cells and tumors (T) in six AdCMVlacZ-injected rats of which samples of two rats were representative for the arterial route, samples of two rats for the portal route and samples of two rats for the intratumoral route. For each tumor, the results were expressed as the mean value obtained from five non contiguous fields (three in the peripheral and two in the center of the tumor).
